Novartis has stood by its commitment to emerging markets even in rocky times. And now, it's furthering that commitment with an access initiative for low-income countries.
Chinese contract drug developer ShangPharma is planning to invest $60 million to build a biologics research and manufacturing outpost near its home base in Shanghai.
Asia's largest vaccinemaker just made a play that could affect the race for a vaccine protecting against dengue fever, a common affliction that has a big impact in the region.
GE Healthcare has staked a major claim in a field that's not well tended--the development of affordable medical technologies to improve health outcomes in the emerging markets. It's creating a devoted business called Sustainable Healthcare Solutions out of a combination of its operations in India, South Asia, Africa and Southeast Asia dedicated to serving 70 markets--and investing $300 million to back the effort.
The middle class in emerging market countries wants diagnostics--and Minneapolis, MN-based Ativa Medical plans to bring it to them via a point-of-care, micro lab designed for the physician office. The startup has secured a $15 million Series B round that's intended to support gaining FDA approval for its micro lab and preparing for commercial launch.
Mindray Medical was off in early trading on the news that a management buyout that was first proposed in June now has a reduced price. The latest offer was for $27 per ADS; that's down from the original offer of $30 per ADS.
GlaxoSmithKline has started work on a new plant in India that is expected to bring hundreds of jobs to the Bangalore area. In the interim, the company's investment for the tablet facility, which will incorporate continuous processing, has grown to £100 million from the £85 initially projected.
Roche CEO Severin Schwan isn't worried about the company's progress in emerging markets. While the helmsman acknowledged a slowdown in China and currency issues in Brazil, the company is still on track to post growth in the long term, Schwan said in an interview with Bloomberg.
The Chinese Food and Drug Administration approved 3-D printed hip implants in China, encouraging innovation amid an increasingly stringent regulatory environment.
Thailand-based pharma manufacturer Mega Lifesciences is partnering with Sydna Farma of Singapore as part of its efforts to expand into Indonesia.